This year kicks off major events and activities for National Council for Prescription Drug Programs that will fortify our ability to effect change at a more rapid pace and scale in the near future. We took a step back in 2019 to assess where we are as an organization, where the industry is heading, and
ARLINGTON, Va. – The National Association of Chain Drug Stores has analyzed the Centers for Medicare & Medicaid Services’ (CMS) proposed Medicare Part D changes, and found progress on topics related to advancing e-prescribing and medication therapy management (MTM); further addressing opioid issues in a pro-patient and pro-pharmacy manner; and fostering pharmacy access. CMS’ approaches
SCOTTSDALE, Ariz. — Lee Ann Stember, president of the National Council for Prescription Drug Programs (NCPDP), has been named as one of the “Most Powerful Women in Healthcare IT” by health care journal Health Data Management. “This is a tremendous honor,” Stember said in a statement. “Just last week we held NCPDP’s 40th Anniversary Conference
SCOTTSDALE, Ariz. — McNeil Consumer Healthcare has joined the National Council for Prescription Drug Programs (NCPDP) Elite Partner Program. NCPDP said Wednesday that the Elite Partner Program establishes the highest level of sustained support for the council’s efforts to advance patient safety and interoperability. Elite Partners make a three-year commitment. The program provides critical support
SCOTTSDALE, Ariz. — AmerisourceBergen Corp. has joined the National Council for Prescription Drug Programs’ Elite Partner Program. NCPDP said Tuesday that as an Elite Partner, AmerisourceBergen will provide critical support of the valuable standards development and other work of NCPDP, including its continuing evolution as a forum for health care business, patient safety issues, education, new product development and the
The National Council for Prescription Drug Programs took part in the meeting that may result in the rollout of the nation’s first biosimilar medication. John Klimek, senior vice president for standards and industry information technology at NCPDP, addressed the Food and Drug Administration’s Center for Drug Evaluation and Research (CDER) and Oncologic Drugs Advisory Committee (ODAC)
